Multiple reports say the United States is reviewing restrictions on compounding certain peptides, including BPC-157, TB-500 and Semax. The articles describe these substances as part of a broader set of compounds that the Biden administration has placed under limits related to compounding. A central reason cited across coverage is the lack of sufficient human clinical trial data. The reviews focus on whether compounding should be allowed given current evidence about safety and effectiveness in humans. The reporting frames the issue as affecting the hyped or rapidly growing market for peptides, while noting that the regulatory approach is tied to evidentiary standards. Although details of the specific review process and scope are not fully specified in the excerpts, both outlets indicate that the underlying regulatory concern is grounded in how much high-quality human clinical data exists. Overall, the coverage presents the development as a regulatory step that could affect access to these peptides through compounding practices in the U.S.